Chiome Bioscience (TSE:4583) Interest Expense : 円-2.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chiome Bioscience's interest expense for the three months ended in Mar. 2024 was 円 -0.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was 円-2.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chiome Bioscience's Operating Income for the three months ended in Mar. 2024 was 円 -322.2 Mil. Chiome Bioscience's Interest Expense for the three months ended in Mar. 2024 was 円 -0.6 Mil. Chiome Bioscience did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chiome Bioscience Interest Expense Historical Data

The historical data trend for Chiome Bioscience's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Interest Expense Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.86

-0.97

-1.32

-2.07

Chiome Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.34	-0.57	-0.57	-0.59	-0.57

Chiome Bioscience Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2.3 Mil.

Chiome Bioscience (TSE:4583) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chiome Bioscience's Interest Expense for the three months ended in Mar. 2024 was 円-0.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was 円-322.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was 円0.0 Mil.

Chiome Bioscience's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Chiome Bioscience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Chiome Bioscience (TSE:4583) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines